For years, $7.2B in U.S. government-backed neuroperformance research sat untouched—proven cognitive enhancements with no commercial application.

David Bach saw the gap. Optios is bridging classified IP with market demand, transforming military-grade neuroscience into real-world performance gains.

The upside? Monumental. The imbalance? Even bigger.

We dive into:

• how declassified DOD research is unlocking a new frontier in neurotech

• the hidden psychology behind winning investor buy-in

• what $600M+ in exits taught him about product-market fit

Connect with us here:

1. David Bach:https://www.linkedin.com/in/david-bach-md-0b81b29/

2. George Bandarian:https://www.linkedin.com/in/georgebandarian/

3. Untapped Ventures:https://www.linkedin.com/company/untappedventures

00:00 Trailer

01:20 Introduction

01:46 David Bach

04:46 Journey to Harvard

10:26 Founding Optios

16:08 Tech Transfer and Market Research

22:09 The Future of Neuro-Performance

28:33 Key Lessons for Founders

33:34 Fundraising Insights

37:29 Closing Thoughts